The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy

Gene Therapy

Volumn 22, Issue 6, 2015, Pages 485-495

  Herrera Carrillo, E ^a   Berkhout, B ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SHORT HAIRPIN RNA; VIRUS RNA;

ARTICLE; COMBINATORIAL LIBRARY; GENE EXPRESSION; GENE THERAPY; GENETIC CONSERVATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; T LYMPHOCYTE; VIRUS GENOME; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; GENE VECTOR; GENETIC VARIATION; GENETICS; HEK293 CELL LINE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

DRUG RESISTANCE, VIRAL; GENETIC THERAPY; GENETIC VARIATION; GENETIC VECTORS; GENOME, VIRAL; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMANS; RNA INTERFERENCE;

EID: 84930483081     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.11     Document Type: Article

References (64)

1. UNAIDS. Reports on the global AIDS epidemic. 2013.
2. Hu WS, Temin HM. Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination. Proc Natl Acad Sci USA 1990; 87: 1556-1560.
3. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988; 242: 1171-1173.
4. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19: 1-7.
5. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med 2012; 18: 182-192.
6. Thomson MM, Najera R. Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev 2005; 7: 210-224.
7. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK et al. HIV-1 nomenclature proposal. Science 2000; 288: 55-56.
8. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11: 507-515.
9. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369: 2083-2092.
10. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van LJ, Rouzioux C et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381: 2109-2117.
11. Llibre JM, Buzon MJ, Massanella M, Esteve A, Dahl V, Puertas MC et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 2012; 17: 355-364.
12. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 2: 36-43.
13. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V et al. Zinc finger nucleasemediated CCR5 knockout hematopoietic stem cell transplantation controls HIV-1 in vivo. Nat Biotechnol 2010; 28: 839-847.
14. Shimizu S, Hong P, Arumugam B, Pokomo L, Boyer J, Koizumi N et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 2010; 115: 1534-1544.
15. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435-438.
16. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-188.
17. Ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 2006; 14: 883-892.
18. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
19. Ter Brake O, Berkhout B. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions. J Gene Med 2007; 9: 743-750.
20. Ter Brake O, Hooft K, Liu YP, Centlivre M, von Eije KJ, Berkhout B. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther 2008; 16: 557-564.
21. von Eije KJ, Ter Brake O, Berkhout B. Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol 2008; 82: 2895-2903.
22. von Eije KJ, Ter Brake O, Berkhout B. Stringent testing identifies highly potent and escape-proof anti-HIV short hairpin RNAs. J Gene Med 2009; 11: 459-467.
23. Ter Brake O, Legrand N, von Eije KJ, Centlivre M, Spits H, Weijer K et al. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model. Gene Ther 2009; 16: 148-153.
24. Eekels JJ, Pasternak AO, Schut AM, Geerts D, Jeeninga RE, Berkhout B. A competitive cell growth assay for the detection of subtle effects of gene transduction on cell proliferation. Gene Ther 2011; 19: 1058-1064.
25. Centlivre M, Legrand N, Klamer S, Liu YP, Eije KJ, Bohne M et al. Preclinical in vivo evaluation of the safety of a multi-shRNA-based gene therapy against HIV-1. Mol Ther Nucleic Acids 2013; 2: e120.
26. Boutimah F, Eekels JJ, Liu YP, Berkhout B. Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors. Antiviral Res 2013; 98: 121-129.
27. Herrera-Carrillo E, Liu YP, Berkhout B. The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS. Mol Ther 2014; 22: 596-606.
28. Herrera-Carrillo E, Paxton WA, Berkhout B. The search for a T cell line for testing novel antiviral strategies against HIV-1 isolates of diverse receptor tropism and subtype origin. J Virol Methods 2014; 203C: 88-96.
29. Deng HK, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997; 388: 296-300.
30. Gao F, Robertson DL, Carruthers CD, Morrison SG, Jian B, Chen Y et al. A comprehensive panel of near-full-length clones and reference sequences for nonsubtype B isolates of human immunodeficiency virus type 1. J Virol 1998; 72: 5680-5698.
31. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM. STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997; 185: 2015-2023.
32. Pollakis G, Abebe A, Kliphuis A, Chalaby MI, Bakker M, Mengistu Y et al. Phenotypic and genotypic comparisons of CCR5-and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol 2004; 78: 2841-2852.
33. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 1997; 71: 8999-9007.
34. Trkola A, Paxton WA, Monard SP, Hoxie JA, Siani MA, Thompson DA et al. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol 1998; 72: 396-404.
35. van 't Wout AB, Blaak H, Ran LJ, Brouwer M, Kuiken C, Schuitemaker H. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection. J Virol 1998; 72: 5099-5107.
36. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365: 1031-1038.
37. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-571.
38. Dupnik KM, Gonzales MJ, Shafer RW. Most multidrug-resistant HIV-1 reverse transcriptase clones in plasma encode functional reverse transcriptase enzymes. Antivir Ther 2001; 6: 42.
39. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995; 206: 527-534.
40. Otto MJ, Garber S, Winslow DL, Reid CD, Aldrich P, Jadhav PK et al. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci USA 1993; 90: 7543-7547.
41. Reuman EC, Bachmann MH, Varghese V, Fessel WJ, Shafer RW. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrasedeleted cloning vector. Antimicrob Agents Chemother 2010; 54: 934-936.
42. Schopman NC, Ter Brake O, Berkhout B. Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology 2010; 7: 52.
43. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15: 4040-4049.
44. Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 2005; 33: 796-804.
45. Martinez MA, Vartanian JP, Wain-Hobson S. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc Natl Acad Sci USA 1994; 91: 11787-11791.
46. Berkhout B, de RA. APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 2004; 18: 1861-1863.
47. Keulen W, Boucher C, Berkhout B. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Res 1996; 31: 45-57.
48. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S. Selection, recombination, and G-A hypermutation of human immunodeficiency virus type 1 genomes. J Virol 1991; 65: 1779-1788.
49. Eekels JJ, Geerts D, Jeeninga RE, Berkhout B. Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors. Antiviral Res 2011; 89: 43-53.
50. Anderson JS, Walker J, Nolta JA, Bauer G. Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization. J Acquir Immune Defic Syndr 2009; 52: 152-161.
51. Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900-909.
52. Westerhout EM, Berkhout B. A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res 2007; 35: 4322-4330.
53. Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 2001; 12: 1893-1905.
54. Falkenhagen A, Ameli M, Asad S, Read SE, Joshi S. Gene therapy using a secreted single chain variable fragment targeting CCR5 to inhibit HIV infection. J Antivir Antiretrovir 2013; 5: 85-91.
55. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26: 808-816.
56. Swan CH, Buhler B, Steinberger P, Tschan MP, Barbas CF III, Torbett BE. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 2006; 13: 1480-1492.
57. Egerer L, Volk A, Kahle J, Kimpel J, Brauer F, Hermann FG et al. Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection. Mol Ther 2011; 19: 1236-1244.
58. van Lunzen J, Glaunsinger T, Stahmer I, von B, V, Baum C, Schilz A et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 2007; 15: 1024-1033.
59. Eggink D, Langedijk JP, Bonvin AM, Deng Y, Lu M, Berkhout B et al. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem 2009; 284: 26941-26950.
60. Eggink D, Bontjer I, Langedijk JP, Berkhout B, Sanders RW. Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol 2011; 85: 10785-10797.
61. Seppen J, Rijnberg M, Cooreman MP, Oude Elferink RP. Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. J Hepatol 2002; 36: 459-465.
62. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P et al. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 1995; 69: 3712-3720.
63. Ter Brake O, Westerink JT, Berkhout B. Lentiviral vector engineering for anti-HIV RNAi gene therapy. Methods Mol Biol 2010; 614: 201-213.
64. Peden K, Emerman M, Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1 LAI, HIV-1 MAL, and HIV-1 ELI. Virology 1991; 185: 661-672.